Imaging features of breast cancer molecular subtypes: state of the art

키워드

참고문헌 (49)

1. Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
2. Sorlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)
3. Prat A, "Clinical implications of the intrinsic molecular subtypes of breast cancer", Breast, 24(Suppl 2), pp.S26~S35 (2015)
4. Coates AS, "Tailoring therapies--improving the management of early breast cancer : St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015", Ann Oncol, 26, pp.1533~1546 (2015)
5. Curigliano G, "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017", Ann Oncol, 28, pp.1700~1712 (2017)
6. Burstein HJ, "Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019", Ann Oncol, 30, pp.1541~1557 (2019)
7. 조나리야, "Molecular subtypes and imaging phenotypes of breast cancer", ULTRASONOGRAPHY, 35(4), pp.281~288 (2016), 대한초음파의학회
8. Lee Seung-Hak, "Radiomics in Breast Imaging from Techniques to Clinical Applications: A Review", Korean Journal of Radiology, 21(7), pp.779~792 (2020), 대한영상의학회[DOI]
9. Leithner D, "Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes : initial results", Breast Cancer Res, 21, pp.106~ (2019)
10. Kim S, "MRI radiomic features : association with disease-free survival in patients with triplenegative breast cancer", Sci Rep, 10, pp.3750~ (2020)
11. Song L, "Preliminary study on discriminating HER2 2+amplification status of breast cancers based on texture features semi-automatically derived from pre-, post-contrast, and subtraction images of DCE-MRI", PLoS One, 15, pp.e0234800~ (2020)
12. Mazurowski MA, "Radiogenomic analysis of breast cancer : luminal B molecular subtype is associated with enhancement dynamics at MR imaging", Radiology, 273, pp.365~372 (2014)
13. Grimm LJ, "Computational approach to radiogenomics of breast cancer : Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms", J Magn Reson Imaging, 42, pp.902~907 (2015)
14. Bae MS, "Quantitative MRI morphology of invasive breast cancer : correlation with immunohistochemical biomarkers and subtypes", Acta Radiol, 56, pp.269~275 (2015)
15. Sutton EJ, "Breast cancer subtype intertumor heterogeneity : MRI-based features predict results of a genomic assay", J Magn Reson Imaging, 42, pp.1398~1406 (2015)
16. Waugh SA, "Magnetic resonance imaging texture analysis classification of primary breast cancer", Eur Radiol, 26, pp.322~330 (2016)
17. Li H, "Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA", TCIA data set, 2016, pp.2, 16012~
18. Agner SC, "Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images : a feasibility study", Radiology, 272, pp.91~99 (2014)
19. Chamming’s F, "Features from computerized texture analysis of breast cancers at pretreatment MR imaging are associated with response to neoadjuvant chemotherapy", Radiology, 286, pp.412~420 (2018)
20. Braman NM, "Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI", Breast Cancer Res, 19, pp.57~ (2017)
21. Chia SK, "A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen", Clin Cancer Res, 18, pp.4465~4472 (2012)
22. Prat A, "Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen", Ann Oncol, 23, pp.2866~2873 (2012)
23. Iwamoto T, "Estrogen receptor(ER)mRNA and ER-related gene expression in breast cancers that are 1% to 10%ER-positive by immunohistochemistry", J Clin Oncol, 30, pp.729~734 (2012)
24. Ng CK, "Breast cancer genomics from microarrays to massively parallel sequencing:paradigms and new insights", J Natl Cancer Inst, 107, pp.djv015~ (2015)
25. Liedtke C, "Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer", J Clin Oncol, 26, pp.1275~1281 (2008)
26. Paik S, "Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer", J Clin Oncol, 24, pp.3726~3734 (2006)
27. Shin HJ, "Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer", Br J Radiol, 84, pp.19~30 (2011)
28. Chae EY, "Association between ultrasound features and the 21-gene recurrence score cssays in patients with oestrogen receptor-positive, HER2-negative, invasive breast cancer", PLoS One, 11, pp.e0158461~ (2016)
29. Yepes MM, "Can mammographic and sonographic imaging features predict the Oncotype DX recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?", Breast Cancer Res Treat, 148, pp.117~123 (2014)
30. Grimm LJ, "Can breast cancer molecular subtype help to select patients for preoperative MR imaging?", Radiology, 274, pp.352~358 (2015)
31. Arteaga CL, "Treatment of HER2-positive breast cancer : current status and future perspectives", Nat Rev Clin Oncol, 9, pp.16~32 (2011)
32. Zhou BP, "Dysregulation of cellular signaling by HER2", neu in breast cancer, 2003, pp.30, 38~48
33. Perez EA, "Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer : joint analysis of data from NCCTG N9831 and NSABP B-31", J Clin Oncol, 29, pp.3366~3373 (2011)
34. Vaz-Luis I, "Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study", Breast Cancer Res., 14, pp.R129~ (2012)
35. Gianni L, "Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer(NOAH) : follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort", Lancet Oncol, 15, pp.640~647 (2014)
36. Elias SG, "Imaging features of HER2overexpression in breast cancer : a systematic review and metaanalysis", Cancer Epidemiol Biomarkers Prev, 23, pp.1464~1483 (2014)
37. Yoon GY, "Imaging and clinicopathologic features associated with pathologic complete response in HER2-positive breast cancer receiving neoadjuvant chemotherapy with dual HER2 blockade", Clin Breast Cancer, 20, pp.25~32 (2020)
38. Choi WJ, "Correlation between magnetic resonance imaging and the level of tumor-infiltrating lymphocytes in patients with estrogen receptor-negative HER2-positive breast cancer", Acta Radiol, 61, pp.3~10 (2020)
39. Nuciforo P, "A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes(CelTIL)in HER2-positive breast cancer treated with chemo-free dual HER2 blockade", Ann Oncol, 29, pp.170~177 (2018)
40. Prat A, "Molecular characterization of basal-like and non-basal-like triplenegative breast cancer", Oncologist, 18, pp.123~133 (2013)
41. Lehmann BD, "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies", J Clin Invest, 121, pp.2750~2767 (2011)
42. Masuda N, "Adjuvant capecitabine for breast cancer after preoperative chemotherapy", N Engl J Med, 376, pp.2147~2159 (2017)
43. Dogan BE, "Imaging of triple-negative breast cancer", Ann Oncol, 23(Suppl 6), pp.vi23~vi29 (2012)
44. Lamb PM, "Correlation between ultrasound characteristics, mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast", Clin Radiol, 55, pp.40~44 (2000)
45. Uematsu T, "Triple-negative breast cancer : correlation between MR imaging and pathologic findings", Radiology, 250, pp.638~647 (2009)
46. Youk JH, "Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusionweighted MR imaging : comparison with other breast cancer subtypes", Eur Radiol, 22, pp.1724~1734 (2012)
47. 김가람, "Associations between gene expression profiles of invasive breast cancer and Breast Imaging Reporting and Data System MRI lexicon", Annals of Surgical Treatment and Research, 93(1), pp.18~26 (2017), 대한외과학회
48. Kawashima H, "Triple-negative breast cancer : are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?", Acad Radiol, 18, pp.963~969 (2011)
49. Bae MS, "Pretreatment MR imaging features of triple-negative breast cancer : association with response to neoadjuvant chemotherapy and recurrence-free survival", Radiology, 281, pp.392~400 (2016)

관련 논문AI추천